Document Detail


Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.
MedLine Citation:
PMID:  12398964     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The myocardial contractile protein myosin light chain 1 isoform (MLC-1) is released into the circulation during myocyte necrosis and could thus be a marker of low-grade myocardial damage and of poor prognosis in patients with heart failure. Two hundred eighteen patients with stable heart failure (ejection fraction [EF] <35%) and in New York Heart Association (NYHA) class III to IV had MLC-1 measured at baseline and 1 month after being randomized to the direct vasodilator flosequinan or placebo. Patients were followed a mean of 302 +/- 142 days. The prognostic value of an increase in MLC-1 above the 98th percentile of normal controls was compared with that of conventional prognostic variables in heart failure. MLC-1 was increased in over half of patients at baseline and 1 month, and this was associated with increased age, NYHA class IV, and renal insufficiency. By Kaplan-Meier survival analysis, patients with a baseline increase in MLC-1 had a greater mortality (26%) than those without an increase (15%) (p = 0.043). A significant interaction among MLC-1, survival, and treatment was found (p = 0.043). In the placebo group, MLC-1 was associated with increased mortality (29% vs 12%, p = 0.025), whereas there was no significant difference among patients receiving flosequinan. In a multivariate logistic regression model including age, treatment, and left ventricular (LV) ejection fraction, the MLC-1 chain was most predictive of mortality (p = 0.049). Thus, circulating MLC-1 is elevated in over half of patients with stable severe heart failure, and this increase is associated with a poor prognosis. Flosequinan treatment eliminates this association, highlighting the complexity of the relation between cardiac myocyte damage, drug treatment, and mortality.
Authors:
Mark S Hansen; Eric B Stanton; Yehia Gawad; Milton Packer; Bertram Pitt; Karl Swedberg; Jean L Rouleau;
Related Documents :
6490214 - Myocardial involvement in acromegaly.
24731654 - A systematic review and collaborative meta-analysis to determine the incremental value ...
8468224 - Severe cardiomegaly secondary to anemia in a kitten.
24532094 - Reduced oxidative stress in stemi patients treated by primary percutaneous coronary int...
21053354 - How to manage no reflow phenomenon with local drug delivery via a rapid exchange catheter.
881754 - Prognostic profile of fascicular blocks in myocardial infarction.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  90     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2002 Nov 
Date Detail:
Created Date:  2002-10-25     Completed Date:  2002-12-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  969-73     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiology of the University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Biological Markers / blood
Double-Blind Method
Female
Follow-Up Studies
Heart Failure / blood*,  drug therapy*,  mortality
Humans
Male
Middle Aged
Multivariate Analysis
Myosin Light Chains / blood*,  drug effects*
North America
Predictive Value of Tests
Prospective Studies
Quinolines / therapeutic use*
Scandinavia
Severity of Illness Index
Stroke Volume / drug effects,  physiology
Survival Analysis
Treatment Outcome
Vasodilator Agents / therapeutic use*
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Myosin Light Chains; 0/Quinolines; 0/Vasodilator Agents; 76568-02-0/flosequinan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous ami...
Next Document:  Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and im...